Failed clinical trials can be fatal for small biotechs that don’t have the backing of big pharma, and even having to alter plans can be prohibitively costly.
The last two decades have seen often limited treatment options for cancers give way to therapies with increasingly complex and targeted mechanisms of action as understanding of the disease
Verily, the life sciences company owned by Google parent Alphabet, has teamed up with Novartis, Sanofi, Otsuka, and Pfizer on a project that aims to speed up clinical trials.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
